Sirt1/2-IN-3

Cat. No.:	HY-155728
CAS No.:	301313-42-8
Molecular Formula:	$C_{17}H_{14}ClNO_4S$
Molecular Weight:	363.82
Target:	Sirtuin; Apoptosis
Pathway:	Cell Cycle/DNA Damage; Epigenetics; Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Sirt1/2-IN-3 (compound PS9) is a dual inhibitor of SIRT1/2 with IC_{50}s of 1.4 μM (SIRT1) and 2.0 μM (SIRT2), respsectivley. Sirt1/2-IN-3 completely blocks p53 deacetylation, and increase of p53 and α-tubulin acetylation. Sirt1/2-IN-3 induces apoptosis and shows anti-proliferation activity against human leukemia cell lines[1].
IC_{50} & Target	IC50: 1.4 μM (SIRT1), 2.0 μM (SIRT2), 72.3 μM (SIRT3)[1]
In Vitro	Sirt1/2-IN-3 (compound hsa55) (5 μM; 48 h) induces apoptosis in different tumor cells, with IC_{50}s of 6.5 μM (MV4-11), 9.2μM (MOLM-13), 27.2 μM (THP1), 17.4 μM (Jurkat), respectively[1].Sirt1/2-IN-3 (100 μM; 30 min) decreases the thermal stability of both SIRT1 and SIRT2 proteins at different temperatures, and also (25 μM, 30 μM; 6 h) increase level of the acetylated form of p53 and α-tubulin in MOLM-13 cells[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Cai H, et al. Discovery of Novel SIRT1/2 Inhibitors with Effective Cytotoxicity against Human Leukemia Cells. J Chem Inf Model. 2023 Aug 14;63(15):4780-4790.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA